Clinical Trials Browser

Mesothelioma, Malignant × Pharmacogenomic Testing × 90 days × Clear all

NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Phase 2 Completed

65 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural